Brief: Imunon Sharpens Focus On Its Promising Pivotal Phase 3 Ovarian Cancer Study
05/02/2026 13:28
Feb 5 (Reuters) - Imunon Inc IMNN.O: IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY IMUNON INC - STRATEGIC RESTRUCTURING TO CUT NON-ESSENTIAL EXPENSES IMUNON INC: PHASE 3 STUDY ENROLLMENT REMAINS AHEAD OF SCHEDULE AND ADVANCES COMPANY TOWARD FUTURE BLA FILING IMUNON INC: ANNOUNCES STRATEGIC REORGANIZATION THAT WILL ELIMINATE HEADCOUNT NOT ESSENTIAL TO PHASE 3 TRIAL IMUNON INC - KHURSHEED ANWER TO RETIRE AS EVP AND CSO Source text: ID:nGNX1cJ9pP Further company coverage: IMNN.O ((Reuters.Briefs@thomsonreuters.com;))